Reserach Purpouses Only
Reserach Purpouses Only
Comming Soon
Comming Soon
FOXO4-DRI - Research Supply
Year
2026
Client
NeoPepp
Timeframe
5 weeks
46-residue engineered senolytic peptide utilizing a D-retro-inverso structural design to resist enzymatic degradation in vitro.
46-residue engineered senolytic peptide utilizing a D-retro-inverso structural design to resist enzymatic degradation in vitro.
The challenge
Designed to disrupt the FOXO4-p53 interaction in senescent cells. The complex D-amino acid reversed sequence is notoriously difficult to synthesize correctly, leading to high failure rates in preclinical apoptosis assays.
Designed to disrupt the FOXO4-p53 interaction in senescent cells. The complex D-amino acid reversed sequence is notoriously difficult to synthesize correctly, leading to high failure rates in preclinical apoptosis assays.
The solution
Uncompromising D-retro-inverso synthesis validated through advanced chromatography. We supply structurally exact FOXO4-DRI, enabling researchers to target senescence pathways without synthesis-related artifacts.
Uncompromising D-retro-inverso synthesis validated through advanced chromatography. We supply structurally exact FOXO4-DRI, enabling researchers to target senescence pathways without synthesis-related artifacts.
Discover other projects
Dive into our diverse collection of innovative projects, where creativity meets cutting-edge technology to solve real-world challenges